Iovance Biotherapeutics, Inc. (IOVA)
Iovance: Buy Now Before Many Growth Catalysts Kick In
Iovance raised 2026 revenue guidance to $410–$420 million as Amtagvi adoption accelerates, supported by expanding treatment access, greater physician awareness, and faster manufacturing. Frontline melanoma trials, lung cancer development, and international expansion could broaden Amtagvi's market by at least an order of magnitude from the current peak sales expectation of $1B. Internal manufacturing supports improving margins and narrowing losses. I project gross margins reaching 65–70%, although continued cash burn and potential dilution remain risks.
Here's Why Iovance Biotherapeutics (IOVA) is a Great Momentum Stock to Buy
Does Iovance Biotherapeutics (IOVA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Iovance Biotherapeutics: Breakout Quarter, Catalysts Ahead, And Competitor Updates
Iovance Biotherapeutics, Inc. delivered a breakout Q2 '26 for Amtagvi sales, with management guiding for further growth ahead. IOVA's maturing clinical pipeline and imminent NSCLC readout position the company for further upside, given the market potential in NSCLC is several times larger than in melanoma. Potential competitor, IMTX, is expecting to produce results from a trial of its cell therapy, Anzu-cel, in melanoma in H1 '27.
IOVA Q2 Earnings Beat, Stock Jumps 43% on Strong Amtagvi Uptake
Iovance rises 43% after Q2 results top estimates as Amtagvi sales beat forecasts, boosting revenues and prompting a review of full-year guidance.
Does Iovance Biotherapeutics (IOVA) Have the Potential to Rally 28.02% as Wall Street Analysts Expect?
The mean of analysts' price targets for Iovance Biotherapeutics (IOVA) points to a 28% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Iovance Biotherapeutics Q2 Earnings Call Highlights
Iovance Biotherapeutics NASDAQ: IOVA reported record second-quarter revenue and gross margin, driven by demand for its Amtagvi tumor-infiltrating lymphocyte, or TIL, therapy, as the company expanded its treatment-center network and advanced clinical programs in lung cancer, sarcoma and gynecologic cancers.
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.33 per share a year ago.
Iovance Biotherapeutics: Commercial, Clinical And Regulatory Tailwinds
IOVA guides for $350M–$370M 2026 revenue (36% YoY growth), with Q2'26 expected to be a record Amtagvi quarter. Expansion into new indications (NSCLC, endometrial, sarcoma) and global markets underpins the pipeline-in-a-drug thesis. A more receptive FDA increases the likelihood of accelerated approvals based on single-arm data, streamlining IOVA's development path.
Iovance Biotherapeutics pushes cell therapy platform into solid tumor market
Iovance Biotherapeutics (NASDAQ:IOVA) said it has obtained clearance of an Investigational New Drug application for IOV-5001, extending its next-generation cell therapy platform into solid tumors the company said account for more than 100,000 US deaths a year. The clearance allows Iovance to begin clinical work on IOV-5001 and marks the platform's move beyond its current focus and into the solid tumor setting.
IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%
Iovance matches Q1 earnings estimates, but weaker-than-expected Amtagvi and Proleukin sales sent shares down 13% despite revenue growth.
Iovance Biotherapeutics, Inc. (IOVA) Q1 2026 Earnings Call Transcript
Iovance Biotherapeutics, Inc. (IOVA) Q1 2026 Earnings Call Transcript
Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue Estimates
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.19 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.36 per share a year ago.
